Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter

RECENT PUBLICATIONS ON RESIDUAL RISK

2020

Pemafibrate in non-alcoholic fatty liver disease?

The ongoing pandemics of obesity, metabolic syndrome and type 2 diabetes have led to escalation in the global prevalence of nonalcoholic fatty liver disease (NAFLD). Worldwide it is estimated that NAFLD affects 25% of the population, with the highest prevalence in the Middle East and South America. Multiple comorbidities are associated with NAFLD, including dyslipidaemia. The clinical profile of pemafibrate, a selective peroxisome proliferator activated receptor ╬▒ modulator (SPPARM╬▒), evident from clinical trials in patients with dyslipidaemia, including improvement in liver function, suggests potential benefit with this agent in the setting of NAFLD. This pilot study aimed to investigate pemafibrate in patients with NAFLD.
 
The study included 20 patients with NAFLD and dyslipidaemia, who received pemafibrate 0.1 mg twice daily. After 12 weeks, treatment with pemafibrate resulted in reduction in serum alanine aminotransferase (ALT) levels, from 75.1 IU/L at baseline to 43.6 IU/L at week 12 (p=0.001). There were also significant improvements in plasma triglycerides and high-density lipoprotein cholesterol levels. On the basis of their findings, further evaluation of pemafibrate for management of NAFLD with dyslipidaemia is merited.
Effect of Pemafibrate on fatty acid levels and liver enzyme in NAFLD patients with Dyslipidemia: a single-arm, pilot study.

Seko Y, Yamaguchi K, Umemura A, et al.